ANTX AN2 Therapeutics, Inc.
Healthcare$4.73-2.47%ClosedMarket Cap: $129.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.02
P/S
0.00
EV/EBITDA
-2.17
DCF Value
$0.59
FCF Yield
-23.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-52.3%
ROA
-39.5%
ROIC
-45.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-10.6M | $-10.0M | $— | — |
| Q4 null | $0.00 | NaN% | $-9.3M | $-8.7M | $— | — |
| FY null | $0.00 | NaN% | $-38.1M | $-35.2M | $— | — |
| Q3 null | $0.00 | NaN% | $-10.0M | $-9.4M | $— | — |
| Q2 null | $0.00 | NaN% | $-7.2M | $-6.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-11.5M | $-10.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-8.6M | $-7.5M | $— | — |
| FY null | $0.00 | NaN% | $-54.6M | $-51.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-14.0M | $-12.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-15.9M | $-14.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-18.3M | $-16.6M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-18.8M | $-16.9M | $-0.57 | — |